RNaseH2 inhibition potentiates temozolomide response in patient derived glioblastoma cells

Abstract Glioblastoma (GBM) is the most common and lethal form of primary brain tumor, characterized by poor prognosis and limited treatment options, with a median survival of only 12 to 15 months post-diagnosis. Despite standard therapeutic protocols involving temozolomide (TMZ) and radiotherapy, e...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Miroslava Kissova, Judit Martinez Segarra, Tobias Solli Iveland, Marthe Vestvik, Erlend Ravlo, Wei Wang, Lars Hagen, Nina-Beate Liabakk, Maria Camara-Quilez, Miquel Arano Barenys, Ole Solheim, Bård Helge Hoff, Eirik Sundby, Magnar Bjørås, Geir Slupphaug, Torkild Visnes, Alessandro Brambilla
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Portfolio 2025-11-01
סדרה:	Scientific Reports
נושאים:	GBM High-throughput screening (HTS) Drug screening
גישה מקוונת:	https://doi.org/10.1038/s41598-025-25298-5
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!